Abstract: In some embodiments, an image sensor mechanically coupled to a base of a camera module. A coil assembly is mechanically coupled to the base of the camera module. The coil assembly includes terminals for connections to respective ones of coils through leads routed through thin areas leading to coil housings. The coils include optical image stabilization coils mounted perpendicular to the image sensor on each of a plurality of faces of the camera actuator module.

Abstract: In some embodiments, the actuator module includes an voice coil motor base, a coil rigidly attached to the voice coil motor base, a lens movement mechanism suspended on the voice coil motor base by a suspension means configured to limit relative motion in linear directions orthogonal to an optical axis of the miniature camera, and a plurality of magnets rigidly mounted to the lens movement mechanism.

Abstract: An actuator module for optical image stabilization of a lens assembly relative to an image sensor in a camera includes a coil mounting structure. A plurality of optical image stabilization (OIS) coils is mounted to the coil mounting structure. Some embodiments include a lens assembly structure configured to hold a lens assembly. A plurality of magnets is affixed to the lens assembly structure. Some embodiments include a spring assembly for coupling the coil mounting structure to the lens assembly structure, such that the lens assembly structure is movable relative to the coil mounting structure in a plane orthogonal to an optical axis of the lens assembly. The lens assembly comprises a light input side and an opposing light exit side for providing light for an image to an image sensor. The plurality of OIS coils is mounted closer to the light input side than the plurality of magnets.

Abstract: A mole trap includes a steel rod frame having parallel spaced legs adapted to penetrate the ground on opposite sides of a mole hill or tunnel. The legs are integrally connected by a handle portion and also by a stop bar, and a spike plate having depending spikes is preloaded against the stop bar by compression springs mounted on the legs. An L-shaped latch lever is pivotally supported by the stop bar and supports a trip plate adapted to contact the ground where the mole tunnel has been depressed. The spike plate and spikes are retracted upwardly against the springs to a set position by pulling a flexible strap extending from the handle portion around a roller supported by the spike plate for rotation on an eccentric axis to provide a mechanical advantage. A roller on the latch lever automatically blocks the spike plate when elevated to the set position.

Abstract: A developer cartridge for containing a developer and for delivering the developer to a developer hopper of an electro-photographic machine. A developer containment portion includes a first portion having an at least partially closed volume configured to contain the developer and a second portion adjacent the first portion and having an opening configured to deliver the developer to the developer hopper. A sealing gasket is disposed adjacent the second portion of the developer containment portion and surrounds at least a portion of a circumference of the opening. A first cover is disposed adjacent the second portion of the developer containment portion and is positionable between an open position for delivery of the developer and a closed position for preventing delivery of the developer. The sealing gasket contacts the first cover to prevent undesired leakage of the developer therebetween.

Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

Abstract: A developer cartridge for containing a developer and for delivering the developer to a developer hopper of an electro-photographic machine. A developer containment portion includes a first portion having an at least partially closed volume configured to contain the developer and a second portion adjacent the first portion and having an opening configured to deliver the developer to the developer hopper. A sealing gasket is disposed adjacent the second portion of the developer containment portion and surrounds at least a portion of a circumference of the opening. A first cover is disposed adjacent the second portion of the developer containment portion and is positionable between an open position for delivery of the developer and a closed position for preventing delivery of the developer. The sealing gasket contacts the first cover to prevent undesired leakage of the developer therebetween.

Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

Abstract: A developer cartridge for containing a developer and for delivering the developer to a developer hopper of an electro-photographic machine. A developer containment portion includes a first portion having an at least partially closed volume configured to contain the developer and a second portion adjacent the first portion and having an opening configured to deliver the developer to the developer hopper. A sealing gasket is disposed adjacent the second portion of the developer containment portion and surrounds at least a portion of a circumference of the opening. A first cover is disposed adjacent the second portion of the developer containment portion and is positionable between an open position for delivery of the developer and a closed position for preventing delivery of the developer. The sealing gasket contacts the first cover to prevent undesired leakage of the developer therebetween.

Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases that may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

Abstract: The invention is directed to methods for identifying agents that affect mitochondrial functions and cell death. Such agents are useful for treating diseases associated with mitochondrial dysfunction and to methods of identifying a risk or presence of such diseases. In particular, the invention relates to the loss of mitochondrial membrane potential (&Dgr;&PSgr;m) during mitochondrial permeability transition (MPT) and further provides a measurable rate loss function, changes in which are useful, inter alia, for detecting agents that affect one or more mitochondrial functions, for detecting mitochondrial diseases and for studying molecular components of mitochondria that regulate MPT.

Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus. Parkinson's Disease, neuronal and cardiac ischemia. Huntington's disease and stroke.

Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondrial protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus. Parkinson's Disease, neuronal and cardiac ischemia. Huntington's disease and stroke.

Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.

Abstract: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.